The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study Group
Top Cited Papers
- 15 November 2003
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (22) , 4112-4119
- https://doi.org/10.1200/jco.2003.01.095
Abstract
Purpose: In early clinical trials with patients receiving highly emetogenic chemotherapy, the neurokinin antagonist aprepitant significantly enhanced the efficacy of a standard antiemetic regimen consisting of a type-three 5-hydroxytryptamine antagonist and a corticosteroid. This multicenter, randomized, double-blind, placebo-controlled phase III study was performed to establish definitively the superiority of the aprepitant regimen versus standard therapy in the prevention of chemotherapy-induced nausea and vomiting (CINV).Keywords
This publication has 33 references indexed in Scilit:
- Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonistsEuropean Journal Of Cancer, 2003
- Prevention of cisplatin‐induced acute and delayed emesis by the selective neurokinin‐1 antagonists, L‐758,298 and MK‐869Cancer, 2002
- The Changeable Nature of Patients' Fears Regarding ChemotherapyJournal of Pain and Symptom Management, 2001
- Potential of Substance P Antagonists as AntiemeticsDrugs, 2000
- The novel NK1 receptor antagonist MK–0869 (L–754,030) and its water soluble phosphoryl prodrug, L–758,298, inhibit acute and delayed cisplatin-induced emesis in ferretsNeuropharmacology, 2000
- Physiology of Chemotherapy-Induced Emesis and Antiemetic TherapyDrugs, 1997
- Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferretsNeuropharmacology, 1996
- Serotonin Mechanisms in Chemotherapy-Induced Emesis in Cancer PatientsOncology, 1996
- Cisplatin and Emesis: Aspects of Treatment and a New Trial for Delayed Emesis Using Oral Dexamethasone plus Ondansetron Beginning at 16 Hours after CisplatinOncology, 1996
- Antiemetic Study Methodology: Recommendations for Future StudiesOncology, 1996